Huakang Biomedical Holdings Company Limited provided earnings guidance for the first quarter ended March 31, 2020. For the period, the Board informed the shareholders of the company and potential investors that the Group is expected to record a significant increase in loss attributable to owners of the company from approximately RMB148,000 for the three months ended 31 March 2019 to approximately RMB2,753,000 for the three months ended 31 March 2020. The Board believes that the expected significant increase in 2020 First Quarterly Loss was mainly attributable to the significant decline in sales revenue in the markets within the People's Republic of China as since the outbreak of the novel coronavirus (COVID-19) epidemic, a number of provinces and municipalities in the PRC have taken emergency public health measures and various actions to prevent the spread of the Epidemic, including crowd-control and/or stay-home policies or orders.